Please assess the completion status of the following clinical trial:

Trial Title: Rheumatoid Arthritis (RA) Moderate to Low Disease Activity Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with established diagnosis of low to moderate adult rheumatoid arthritis, currently on Disease Modifying AntiRheumatic Drugs (DMARDs) therapy for at least six months and not longer than 10 years~Exclusion Criteria:~* All the concomitant diseases or pathological conditions that could interfere and impact the assessment of the study treatment, or with the safety of the patient~* Previous clinical trials and previous biological therapy that could interfere with the results in the present clinical trial~* Patients must not have received any previous biological therapy for rheumatoid arthritis (RA)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Certolizumab pegol 200 mg (CDP870) (Type: EXPERIMENTAL): Two 200 mg subcutaneous injections at Week 0, Week 2, and Week 4 followed by 200 mg injections every 2 weeks until the last drug administration (Week 22)
- Placebo (Type: PLACEBO_COMPARATOR): Two 0.9% saline subcutaneous injections at Week 0, Week 2, and Week 4 followed by 0.9% saline injections every 2 weeks until the last drug administration (Week 22)

Based on this trial design, predict the completion outcome and termination type (if applicable).